2021 BRN Discussion, page-10615

Hi all

We know that Brainchippartnered with Biotome to do thefollowing:

“The Akida neuromorphic processor chip will be used tointerpret sensor responses and to find out which responses are the mostrepresentative for antibodies that are protective. The objective of the Biotomeresearch project is to create a handheld device that uses nanomaterial-basedsensors in combination with the Akida chip that will give accurate results inseconds.”

https://hotcopper.com.au/threads/biotome-partnership.6067692/

We know that Biotome Pty Ltd announced an additionalpartnership with Cardea Bio Inc to do the following but where does Brainchipfit in you might ask so read on:

“Perth, Australia – May 4, 2021 -Precision diagnostics company BiotomePty Ltd has entered into a technology partnership with CardeaBio Inc, a global leader in nanoelectronics manufacturing and the only mass-producer of graphene-based biological transistors. Through Biotome joining Cardea’s Innovation Partnership Program, the companies can work together to leverage Cardea’s proprietary Cardean Transistor™ technology for the development of electrochemical biosensors for precision immunology diagnostics.

Bornout of Nobel Prize winning concepts, Biotome’s novel technology integrateslinear epitopes with diagnostic assay platforms to mimic the intrinsichigh-resolution of the immune system. This results in higher precision andlower cost compared to conventional serology.

Throughtheir technology, Biotome discovers patentable immunological markers ofsuperior accuracy across a range of diseases, including infections, cancers andautoimmunity. Biotome has a strong application portfolio, including patentedand patent pending markers for stomach cancer risk (Helitope®) and SARS-CoV-2infection (Covitope®).

“Webelieve antibody-tests can be improved dramatically. Antibody/serology testingduring the COVID-19 pandemic has highlighted glaring inaccuracy issues withinfection diagnostics.” Dr Samuel Lundin, Founder and CEO of Biotome. “Thisimportant partnership sets up a solid technology foundation andcommercialisation pathway for our patented immunological markers, and we arevery excited to be using cutting-edge graphene-based technology to unlock thehigh resolution of the immune system.”

Thepartnership will leverage Cardea’s graphene field effect transistors to connectbiology with modern electronics for high-precision immunology diagnostics, toaddress the unparalleled global demand for rapid, accurate diagnostic tests.”

https://www.biotome.com.au/post/biotome-announces-partnership-with-cardea-bio-to-develop-graphene-based-precision-immunology-point-o

Cardio Bio Inc does the following:

“Cardea’s Tech+Bio Infrastructure

Cardea’s Tech+BioInfrastructure has created a paradigm shift in Life Science andtechnology with the development and introduction of biology being directlyintegrated into modern electronics. Comprised of Tech+Bio modules, the Tech+BioInfrastructure is exclusively offered to our Innovation Partners who are ready todevelop a new generation of products that “Link up to Life” and allow us all touse “Biology as Technology”.

We use ourBiology-gated Transistors, or Cardean Transistors™, as core modules to buildchipsets, such as CRISPR-Chip™, that can be configured and integrated intothousands of potential products and applications to be used in the field, atthe bedside, or at the bench. Connecting electronics directly to biology is afundamental change in how life science signal detection has been done up untilnow. This is opening up a new world where we can have products that utilizesystem biology’s vast range of live signals as interactive data-streams, thatwith time will link system biology directly up to our computers, phones and theInternet.

Our Tech+Bio Infrastructurecombines molecular biology, semiconductor material (graphene), nano-physics andadvanced electronics, the computational power of software, and ML/AI to providea signal detection system that can be configured to each Partner’s needs. Thissystem captures and delivers real-time insight to the biology of interest inorder to develop and commercialize a new generation of products that “Link upto Life”.

THE CORECardean Transistors

It starts with achip composed of biocompatible material graphene to tap into biologicalsignals. While the chip is only part of the solution, Cardea is the onlycompany in the world to have mastered the extreme complexity of mass-producingbiological transistors using graphene, making the chip foundational toevery Powered by Cardea product and application we build. CardeanTransistors can be combined with small bits of biology to create chipsets thatcan be integrated to thousands of different applications. Read about how CRISPR-Chip,a chipset configured with thousands of CRISPR-dcas9 molecules, can be used as aDNA search engine.

THE CIRCUITRYSoftware

With Cardeanmachine learning, direct multi-omics data-streams of biological signals can beused to train ML/AI algorithms on how the sub-systems of biology functions.Using a cloud-based system, Innovation Partners can access and act on streamsof signals anywhere in real-time.

THE ARCHITECTUREHardware

Cardea createsversatile hardware from handheld portable devices that can be run in the field,to automated high-throughput systems on the lab bench.”

https://www.crisprqc.com/crispr-bind/

Brainchip’s AKD1000 will take away the need for acloud-based system (see The Circuitryabove) thus completing the missing link and creating a truly portable device. Imagine what a DNA search engine in a handhelddevice will do for medical transplants, personalised medicine and Policeinvestigations.

A wonderous new world is opening thanks to the trulyunique in the world AKIDA technology combined with Biotome and Cardea.

My opinion only DYOR

FF.

AKIDA Ballista